Last 12 months
Inside the activity.
2 purchase rows · 107 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 2 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 12 |
| Jul 2026 | 0 | 26 |
| Aug 2026 | 0 | 18 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 9 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2018 Filed Aug 22, 2018 21:54 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 35,681 | $12.92 | $461,094.86 |
DisclosureSEC source: 0001225208-18-012868 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,834,793 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.789 to $13.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:42 UTC |
BRADBURY DANIELDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023082 · doc4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:39 UTC |
MAHONEY DAVID LDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023081 · doc4.xml · derivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:38 UTC |
GALA RENEE DDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023078 · doc4.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:39 UTC |
WILSON JAMES NDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023080 · doc4.xml · derivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:35 UTC |
Swisher Daniel N JRDirector
|
GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023070 · doc4.xml · derivative · entry 1 Swisher Daniel N JR · CIK 0001323113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 22:19 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 5,792 | $12.80 | $74,117.33 |
DisclosureSEC source: 0001225208-18-012759 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,799,112 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.60 to $12.80, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 22:19 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 100,000 | $12.49 | $1,248,760.00 |
DisclosureSEC source: 0001225208-18-012759 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,793,320 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.315 to $12.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:51 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 79,686 | $12.49 | $994,967.36 |
DisclosureSEC source: 0001225208-18-012682 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,693,320 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $16.00 to $16.22, inclusive, on May 11, 2018. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reporting person has paid to the issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F4 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 21:51 UTC |
BAKER G LEONARD JRDirector
|
PurchaseCommon Stock | 100,000 | $12.47 | $1,247,000.00 |
DisclosureSEC source: 0001225208-18-012682 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,838 F1 · kind: The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $16.00 to $16.22, inclusive, on May 11, 2018. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.40 to $12.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:20 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-021699 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:20 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $14.15 | $113,184.80 |
DisclosureSEC source: 0000899243-18-021699 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.05 to $14.29 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:20 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-021699 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 23:50 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-019677 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 23:50 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $15.09 | $120,685.60 |
DisclosureSEC source: 0000899243-18-019677 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $14.74 to $15.31 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| July 06, 2018 Filed Jul 9, 2018 23:50 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-019677 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 22:44 UTC |
WILSON JAMES NDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000899243-18-019004 · doc4.xml · derivative · entry 4 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 10,000 shares Expires 2019-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 22:44 UTC |
WILSON JAMES NDirector
|
Exercise / conversionCommon Stock | 10,000 | $2.30 | $23,000.00 |
DisclosureSEC source: 0000899243-18-019004 · doc4.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:07 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-016051 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:07 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $18.23 | $145,825.60 |
DisclosureSEC source: 0000899243-18-016051 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $17.90 to $18.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 21:07 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-016051 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:27 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-18-013255 · doc4.xml · derivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:27 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 10,000 | $2.24 | $22,400.00 |
DisclosureSEC source: 0000899243-18-013255 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 20,000 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| May 15, 2018 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,622 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:30 UTC |
BAKER G LEONARD JRDirector
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 30,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001225208-18-009351 · doc4.xml · derivative · entry 5 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:30 UTC |
BAKER G LEONARD JRDirector
|
SaleCommon Stock | 30,000 | $16.01 | $480,312.00 |
DisclosureSEC source: 0001225208-18-009351 · doc4.xml · nonDerivative · entry 2 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,838 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.22, inclusive. The reporting person undertakes to provide to Corcept Therapeutics Incorporated, and any security holder of Corcept Therapeutics Incorporated, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:30 UTC |
BAKER G LEONARD JRDirector
|
Exercise / conversionCommon Stock | 30,000 | $2.23 | $66,900.00 |
DisclosureSEC source: 0001225208-18-009351 · doc4.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 806,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares. Read SEC document |
| May 07, 2018 Filed May 8, 2018 22:54 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-011920 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| May 07, 2018 Filed May 8, 2018 22:54 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $17.68 | $141,428.00 |
DisclosureSEC source: 0000899243-18-011920 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $17.55 to $17.775 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| May 07, 2018 Filed May 8, 2018 22:54 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-011920 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| May 07, 2018 Filed May 10, 2018 22:24 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012440 · doc4.xml · nonDerivative · entry 2 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,345,202 F1 · balance_after: Reflects the corrected amount of shares which was previously inadvertently misstated. F2 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 21:57 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-009783 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 21:57 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $16.22 | $129,784.00 |
DisclosureSEC source: 0000899243-18-009783 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.91 to $16.63 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 21:57 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-009783 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| March 13, 2018 Filed May 10, 2018 22:24 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 10,665 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012440 · doc4.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,361,202 F1 · balance_after: Reflects the corrected amount of shares which was previously inadvertently misstated. F2 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2018 Filed Mar 8, 2018 01:38 UTC |
GALA RENEE DDirector
|
PurchaseCommon Stock | 9,000 | $15.53 | $139,801.50 |
DisclosureSEC source: 0000899243-18-006756 · doc4.xml · nonDerivative · entry 2 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Represents the weighted average purchase price for the entire number of shares purchased. The actual purchase prices range from $15.5334 to $15.5399 per share. Detailed information on the exact number of shares purchased at each purchase price can be obtained from the issuer upon request. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:11 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-006846 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:11 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $15.67 | $125,323.20 |
DisclosureSEC source: 0000899243-18-006846 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.34 to $15.88 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:11 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-006846 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 01:38 UTC |
GALA RENEE DDirector
|
PurchaseCommon Stock | 1,000 | $15.30 | $15,300.00 |
DisclosureSEC source: 0000899243-18-006756 · doc4.xml · nonDerivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:15 UTC |
Robb Gary CharlesChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003472 · doc4.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:15 UTC |
BELANOFF JOSEPH KDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003471 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC |
FISHMAN ROBERT SChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · derivative · entry 4 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-02-07 F4 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $16.60 | $132,774.40 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $16.34 to $16.93 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:12 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionCommon Stock | 8,000 | $3.51 | $28,080.00 |
DisclosureSEC source: 0000899243-18-003469 · doc4.xml · nonDerivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:10 UTC |
Maduck SeanSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003467 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 22:05 UTC |
FISHMAN ROBERT SChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0000899243-18-000874 · doc4.xml · derivative · entry 3 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,000 Underlying: Common Stock · 8,000 shares Expires 2025-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F3 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number at the first anniversary of September 28, 2015. Thereafter, 1/48th of the total number of shares subject to this option grant vests and becomes exercisable on each monthly anniversary, so that the total number of shares subject to this option becomes fully vested and exercisable on September 28, 2019. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 22:05 UTC |
FISHMAN ROBERT SChief Medical Officer
|
SaleCommon Stock | 8,000 | $18.67 | $149,348.80 |
DisclosureSEC source: 0000899243-18-000874 · doc4.xml · nonDerivative · entry 2 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to the terms of a 10b5-1 plan in effect at the time of sale of the shares. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $18.34 to $18.91 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.